A-431 (CRL-1555) cancer cell line was established by DJ Giard and SA Aaronson from the solid tumor of a female patient suffering from epidermoid carcinoma; in cancer research, A431 cell line is used in medical research to study oncology treatments of skin cancer and is commonly used as a transfection host cell line.
A431 transfection reagent is manufactured by Altogen Biosystems and has been reported to have a 81% transfection efficacy for the delivery of small RNA molecules. This reagent is functionally tested in vitro and has been proven to facilitate the development of A431 stable cell lines. In addition, A-431 transfection reagents for epidermoid carcinoma cell line work in the presence of serum and it is used in both reverse and standard transfection protocols.
Transfection Reagent for A431 Cells
A431 transfection reagent is manufactured by Altogen Biosystems and has been reported to have a 81% transfection efficacy for the delivery of small RNA molecules. This reagent is functionally tested in vitro and has been proven to facilitate the development of A431 stable cell lines. In addition, A-431 transfection reagents for epidermoid carcinoma cell line work in the presence of serum and it is used in both reverse and standard transfection protocols.
Transfection Reagent for A431 Cells